(Total Views: 485)
Posted On: 05/13/2025 9:31:22 PM
Post# of 153103
Old but definitely worth a read again.
https://www.biospace.com/embattled-cytodyn-se...ugh-tumors
“These are both areas where checkpoint inhibitors have failed to show efficacy when added to a standard-of-care backbone, Arman said, adding that leronlimab has shown positive signals in both.
“From a mechanistic standpoint, we believe we could get a synergistic effect with a checkpoint inhibitor,” he said.
Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center.
Arman said CytoDyn expects to observe an enhanced anti-tumor effect from the combination and identify immunological biomarkers.
In terms of future partnerships, Arman isn’t concerned that CytoDyn’s history will have a negative effect.“
And this link
https://www.biospace.com/cytodyn-announces-st...ockade-icb
https://www.biospace.com/embattled-cytodyn-se...ugh-tumors
“These are both areas where checkpoint inhibitors have failed to show efficacy when added to a standard-of-care backbone, Arman said, adding that leronlimab has shown positive signals in both.
“From a mechanistic standpoint, we believe we could get a synergistic effect with a checkpoint inhibitor,” he said.
Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center.
Arman said CytoDyn expects to observe an enhanced anti-tumor effect from the combination and identify immunological biomarkers.
In terms of future partnerships, Arman isn’t concerned that CytoDyn’s history will have a negative effect.“
And this link
https://www.biospace.com/cytodyn-announces-st...ockade-icb
(8)
(0)Scroll down for more posts ▼
